Petros Pharmaceuticals (Petros Pharmaceuticals) Market Cap : $4.27 Mil (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Petros Pharmaceuticals's share price for the quarter that ended in Mar. 2024 was $1.48. Petros Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 6.88 Mil. Therefore, Petros Pharmaceuticals's market cap for the quarter that ended in Mar. 2024 was $10.19 Mil.

Petros Pharmaceuticals's quarterly market cap increased from Sep. 2023 ($3.67 Mil) to Dec. 2023 ($4.22 Mil) and increased from Dec. 2023 ($4.22 Mil) to Mar. 2024 ($10.19 Mil).

Petros Pharmaceuticals's annual market cap declined from Dec. 2021 ($68.88 Mil) to Dec. 2022 ($4.84 Mil) and declined from Dec. 2022 ($4.84 Mil) to Dec. 2023 ($4.22 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Petros Pharmaceuticals's Enterprise Value for Today is $2.11 Mil.

Petros Pharmaceuticals Market Cap Historical Data

The historical data trend for Petros Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Market Cap Chart

Petros Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

42.71

68.88

4.84

4.22

Petros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial													2.91	4.30	3.67	4.22	10.19

Competitive Comparison of Petros Pharmaceuticals's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Market Cap falls into.

Petros Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Petros Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$1.41	*	2.99138
	=	$4.22

Petros Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$1.48	*	6.88186
	=	$10.19

Petros Pharmaceuticals (NAS:PTPI) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Petros Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.petrospharma.com

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley	director	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman	director, 10 percent owner
Jcp Iii Sm Aiv, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan	officer: Chief Financial Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor	officer: Pres. & Chief Comm. Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek	officer: President, Timm Medical	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold	officer: Prin. Acct. Off/Prin. Fin. Off	200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726